Differences between AML with MD-related changes and AML with mutated NPM1
| Feature . | AML with MD-related changes . | AML with mutated NPM1 . |
|---|---|---|
| Nucleophosmin | Nuclear (unmutated) | Cytoplasmic (mutated) |
| WBC count | Often severe pancytopenia | Usually high WBC count |
| Previous history of MDS or MDS/MPN | Frequent | Usually absent |
| Karyotype | Usually abnormal | Usually normal (85%) |
| CD34 | Usually positive | Usually negative |
| Prognosis | Usually poor | Favorable (if FLT3-ITD absent) |
| Feature . | AML with MD-related changes . | AML with mutated NPM1 . |
|---|---|---|
| Nucleophosmin | Nuclear (unmutated) | Cytoplasmic (mutated) |
| WBC count | Often severe pancytopenia | Usually high WBC count |
| Previous history of MDS or MDS/MPN | Frequent | Usually absent |
| Karyotype | Usually abnormal | Usually normal (85%) |
| CD34 | Usually positive | Usually negative |
| Prognosis | Usually poor | Favorable (if FLT3-ITD absent) |
WBC indicates white blood cell.